SAN DIEGO--(BUSINESS WIRE)--Apricus Biosciences, Inc., (“Apricus Bio”) (Nasdaq: APRI) today announced data from animal studies showing that the NexACT® technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption. A total of 10 small molecule therapeutic drugs with known low solubility and/or permeability, according to the Biopharmaceuticals (“BCS”) Classification System, were selected for these studies, and represented the following classes: anti-inflammatory drugs, diuretics, anti-hypertensives, antibiotics, anti-psychotics, anti-Parkinson agents and proton pump inhibitors.
